These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36157294)

  • 1. Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy.
    Ramos-Platt L; Elman L; Shieh PB
    Int J Gen Med; 2022; 15():7341-7353. PubMed ID: 36157294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I.
    Mirea A; Shelby ES; Axente M; Badina M; Padure L; Leanca M; Dima V; Sporea C
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.
    Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W
    Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 6. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam.
    Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A
    Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study.
    Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M
    JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
    Erdos J; Wild C
    Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment.
    Monnette A; Chen E; Hong D; Bazzano A; Dixon S; Arnold WD; Shi L
    Orphanet J Rare Dis; 2021 Jan; 16(1):36. PubMed ID: 33472673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
    Pacione M; Siskind CE; Day JW; Tabor HK
    J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment.
    Nigro E; Grunebaum E; Kamath B; Licht C; Malcolmson C; Jeewa A; Campbell C; McMillan H; Chakraborty P; Tarnopolsky M; Gonorazky H
    Front Neurol; 2023; 14():1230889. PubMed ID: 37780708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment.
    Pierzchlewicz K; Kępa I; Podogrodzki J; Kotulska K
    Child Neurol Open; 2021; 8():2329048X211008725. PubMed ID: 33997096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis.
    Khuntha S; Prawjaeng J; Ponragdee K; Sanmaneechai O; Srinonprasert V; Leelahavarong P
    Appl Health Econ Health Policy; 2024 Sep; ():. PubMed ID: 39333302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy.
    René CA; Parks RJ
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy.
    D'Silva AM; Holland S; Kariyawasam D; Herbert K; Barclay P; Cairns A; MacLennan SC; Ryan MM; Sampaio H; Smith N; Woodcock IR; Yiu EM; Alexander IE; Farrar MA
    Ann Clin Transl Neurol; 2022 Mar; 9(3):339-350. PubMed ID: 35170254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy.
    Kotulska K; Fattal-Valevski A; Haberlova J
    Front Neurol; 2021; 12():726468. PubMed ID: 34721262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians.
    Ramdas S; Oskoui M; Servais L
    Drugs; 2024 Jul; 84(7):747-762. PubMed ID: 38878146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges.
    Messina S; Sframeli M
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32668756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.